MedTrace Logo

CyberKnife Radiosurgery for Organ-Confined Prostate Cancer: Homogenous Dose Distribution

NCT00643994 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 379

Last updated 2023-05-09

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the effects of CyberKnife radiosurgery in patients with early stage organ-confined prostate cancer.

Conditions

  • Prostate Cancer
  • Prostatic Cancer
  • Prostate Neoplasms
  • Prostatic Neoplasms
  • Cancer of the Prostate

Interventions

RADIATION

CyberKnife Stereotactic Radiosurgery

36.25 Gy delivered in 5 fractions of 7.25 Gy per fraction

Sponsors & Collaborators

  • Accuray Incorporated

    lead INDUSTRY

Principal Investigators

  • Robert Meier, MD · Swedish Cancer Center

  • Irving Kaplan, MD · Beth Israel Deaconess Medical Center

  • Martin Sanda, MD · Beth Israel Deaconess Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-12-31
Primary Completion
2021-01-27
Completion
2021-01-27

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00643994 on ClinicalTrials.gov